Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13938254 | 0.84 | CA12 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19CA12 | |
| SCHEMBL4001978 | 0.83 | RHOA (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL13686400 | 0.82 | TNF (0.38) | CYP1A2CYP3A4KMT2AMAPK1LMNA | |
| SCHEMBL3920426 | 0.78 | MAPT (0.44) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3924187 | 0.77 | HPGD (0.43) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3926561 | 0.75 | EGFR (0.35) | KMT2ALMNAHTTHSD17B10TSHR | |
| SCHEMBL5097658 | 0.75 | ALDH1A1 (0.54) | CA12CA2CA9KMT2APKM | |
| SCHEMBL4889051 | 0.71 | HSD17B10 (0.51) | KMT2AMAPK1PKMLMNAHTT | |
| SCHEMBL27490082 | 0.69 | RECQL (0.41) | KMT2AMAPK1PKMLMNAIDO1 | |
| SCHEMBL13938221 | 0.69 | CA12 (0.40) | CA12CA2CA9KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| US-7479489-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-01-20 | — | — | US | disclosed |
| WO-2008051637-A2 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090814-A1 | PYRIDAZINONE COMPOUNDS | HAVCR2, PLPBP, CYP3A43 | CYP1A2 30/4885CYP3A4 11/4885CYP2D6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.